prostate cancer
Conditions
Interventions
Gold Standard:Clinical outcomes: PSA-related biochemical-progression-free survival (bPFS), radiology progression-free survival (rPFS), cancer-specific survival (CSS)
were 
subjected 
to 
in 
experiments 
endocrine 
drugs 
the 
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
Male
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Suspected prostate cancer patients with clinical high-risk factors (such as serum prostate specific antigen level >=20ng/ml); 2. Received prostate magnetic resonance scan before puncture; 3. Agree to undergo prostate biopsy; 4. Agree to continue to receive treatment and follow-up in our hospital after diagnosis; 5. After diagnosis, patients need to receive any form of endocrine therapy (including neoadjuvant endocrine therapy, adjuvant endocrine therapy, systemic therapy based on endocrine therapy or endocrine therapy combined with cytotoxic drug chemotherapy) based on the assessment of the condition; 5. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1. The patient refused to undergo a prostate biopsy; 2. The patient refused to continue to receive treatment and follow-up in our hospital after the diagnosis; 3. After the patient is diagnosed, according to the tumor stage and grade, it is found that it meets the indications for radiotherapy and the patient needs to receive radiotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA-related biochemical-progression-free survival;radiology progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| cancer-specific survival; | — |
Countries
China
Contacts
Public ContactLimin Zhang
Huashan Hospital, Fudan University
Outcome results
None listed